Peptide LibraryPTD-DBM
Also known as: Protein transduction domain–DBM, CXXC5 inhibitor peptide
PTD-DBM (also called Protein transduction domain–DBM or CXXC5 inhibitor peptide) is a hair-follicle Wnt research peptide. PTD-DBM is a fusion of a protein transduction domain, which carries the molecule across cell membranes, with a peptide derived from the Dishevelled-binding motif.
For research use only.
Key Facts
- CAS
- 1609454-11-6
- Molecular Weight (MW)
- 3082.6 g/mol
- Half-life
- —
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- CXXC5–Dvl interactionWnt pathway
Vendor price snapshot
Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected in Oct 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 1
- Listed offers
- 1
- Price per mg
- $16.00/mg
Research summary
Cell-penetrating peptide designed to block CXXC5–Dishevelled binding and enhance Wnt signaling in hair-growth mouse models. Not FDA-approved.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studies3 reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's PTD-DBM profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
PTD-DBM dosage: no established human dose
PTD-DBM has no established human dosage. It is a cell-penetrating peptide designed to block CXXC5 binding to Dishevelled and so switch on Wnt signalling, and it has only been studied in mice and cells. The mouse studies report faster hair regrowth and better wound healing, and their abstracts do not state the amounts used.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: PTD-DBM comes from one research group's work on CXXC5, a protein found at higher levels in balding human scalp. Every in vivo result is in mice, often in combination with valproic acid. No study has applied PTD-DBM to people, so neither a topical strength nor an injected amount is established.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Preclinical — CXXC5-competing peptide and hair regrowth in mice (2017)Preclinical · Animal and cell study | Mice; human balding scalp tissue and hair follicle cells for the CXXC5 findings | Not stated in the indexed abstract (non-human) | Not stated in the indexed abstract | — | — | Activated Wnt/beta-catenin signalling and accelerated hair regrowth and wound-induced hair follicle formation | Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis. J Invest Dermatol. 2017. |
| Preclinical — PTD-DBM in prostaglandin D2-induced hair loss in mice (2023)Preclinical · Animal study | Mice | Not stated in the indexed abstract (non-human) | Not stated in the indexed abstract | — | — | Reversed hair loss caused by prostaglandin D2, including in a wound-induced hair growth model | CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD(2). Cells. 2023. |
| Preclinical — hydrogel patch with PTD-DBM and valproic acid for wounds in mice (2023)Preclinical · Animal study of a combination with valproic acid | Mice with skin wounds | Not stated in the indexed abstract (non-human) | Applied to the wound in a hyaluronic acid patch | — | — | Less scarring during wound healing | Adhesive Hydrogel Patch-Mediated Combination Drug Therapy Induces Regenerative Wound Healing through Reconstruction of Regenerative Microenvironment. Adv Healthc Mater. 2023. |
Where sources disagree
- Several of the mouse results come from PTD-DBM combined with valproic acid. They do not show what PTD-DBM does on its own.
- A concentration in a research formulation is not a dose for injection.
Reconstitution
Common research vial sizes: 5 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL | 25 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Timing Notes
- Educational catalog only — not medical advice
Sequence & molecular data
| Molecular formula | C124H225N61O28S2 |
|---|---|
| Molecular weight | 3082.6 g/mol |
| CAS number | 1609454-11-6 |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 176453931 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
PTD-DBM is a fusion of a protein transduction domain, which carries the molecule across cell membranes, with a peptide derived from the Dishevelled-binding motif. It targets CXXC5, a negative regulator of Wnt signalling that binds Dishevelled and prevents it from transducing the Wnt signal. By competitively disrupting the CXXC5-Dishevelled interaction, the peptide relieves that inhibition and allows beta-catenin to accumulate and drive transcription. Because Wnt/beta-catenin signalling controls the transition of hair follicles from telogen into anagen, this was investigated for hair growth, and mouse studies report anagen induction, particularly when combined with valproic acid. Evidence is preclinical with no human trials.
Origin
Synthetic protein-transduction-domain peptide.
Targets
Studies
- Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/ß-Catenin Signaling, and Emerging Therapies
- CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD(2)
- Adhesive Hydrogel Patch-Mediated Combination Drug Therapy Induces Regenerative Wound Healing through Reconstruction of Regenerative Microenvironment
- The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing
Research statistics
3 PubMed publications · 0.0% human clinical research · 0 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
PTD-DBM is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
PTD-DBM side effects
PTD-DBM has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Unknown human safety
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Cosmetic peptides in this library are formulated into topical products; follow the product label rather than the reconstitution guidance above.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
PTD-DBM: frequently asked questions
What is PTD-DBM?
Cell-penetrating peptide designed to block CXXC5–Dishevelled binding and enhance Wnt signaling in hair-growth mouse models. Not FDA-approved.
How does PTD-DBM work?
PTD-DBM is a fusion of a protein transduction domain, which carries the molecule across cell membranes, with a peptide derived from the Dishevelled-binding motif. It targets CXXC5, a negative regulator of Wnt signalling that binds Dishevelled and prevents it from transducing the Wnt signal.
Is PTD-DBM FDA approved?
No. PTD-DBM is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to PTD-DBM?
Compounds most often compared with PTD-DBM include Acetyl Hexapeptide-8, Acetyl Octapeptide-3, Acetyl Tetrapeptide-3 and AHK-Cu. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/ß-Catenin Signaling, and Emerging Therapies — Cells, 2025External reference
- CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD(2) — Cells, 2023External reference
- Adhesive Hydrogel Patch-Mediated Combination Drug Therapy Induces Regenerative Wound Healing through Reconstruction of Regenerative Microenvironment — Adv Healthc Mater, 2023External reference
- The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing — J Exp Med, 2015External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This PTD-DBM profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track PTD-DBM research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →